Review: Breaking From Bisphosphonates. - sprookjes - yvandenbroek - TriplyDB

Review: Breaking From Bisphosphonates.

Review: Breaking From Bisphosphonates.

http://www.wikidata.org/entity/Q38992765

about

Review: Breaking From Bisphosphonates.

http://www.wikidata.org/entity/Q38992765

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Review: Breaking From Bisphosphonates.

@en

type

label

Review: Breaking From Bisphosphonates.

@en

prefLabel

Review: Breaking From Bisphosphonates.

@en

P1433

Q38992765-EF4426EF-EC1F-4ECF-9AA5-964E3A6D7D33

P1476

Q38992765-E90C7099-E29F-4802-A589-021AE1AE4DC8

P2093

Q38992765-B3989D0E-D32E-4235-8115-34BEE7D4A4DA

P2860

Q38992765-00629366-74B1-4CCD-B98B-9AF200786561

Q38992765-150D031E-6BD3-47FC-AEE5-EC3F6A8AA9EB

Q38992765-2D75B355-3184-4202-B63F-7CE9F37A1560

Q38992765-32023CEF-4DAF-4112-A042-E0B9B369AD66

Q38992765-324C3D8A-58F3-4133-857D-2BC83E3F9E4E

Q38992765-4694235B-4905-4EA2-B143-709123C583DF

Q38992765-59CE32D7-7857-4584-9A06-1D72E89A17BF

Q38992765-5D0D0887-2AFE-4542-9015-B04A66EA3C57

Q38992765-5DBE685F-F6AD-44CB-A6E3-49861A74CE04

Q38992765-60EED3C2-FBC0-40CE-9DF6-2E259DBFBFAD

P304

Q38992765-B76824DA-01A6-4199-9DB0-796019899F64

P31

Q38992765-3C2EEFA3-82EF-4D14-953F-A24A822DC590

P356

Q38992765-590E725F-AC6C-47C5-BA5E-2860C509E7E4

P433

Q38992765-4316A5EF-8117-4262-80B3-7E10427AF1E4

P478

Q38992765-7868D4D0-37A4-4A8D-8565-BD013D7D2E93

P577

Q38992765-49E44D0E-B1FD-406A-8E2F-649810E6E3DF

P698

Q38992765-CD88E41E-99CB-4F8E-9FA3-01562FE11BC6

P356

P1433

Arthritis & Rheumatology

P1476

Review: Breaking From Bisphosphonates.

@en

P2093

Margaret Seton

http://www.w3.org/2001/XMLSchema#string

P2860

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Bisphosphonates for osteoporosis--where do we go from here?

Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

P304

494-498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.39967

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27788292

http://www.w3.org/2001/XMLSchema#string